Efficacy of Cytokine-Induced Killer Cell Immunotherapy for Patients With Pathologically Pure Glioblastoma

Efficacy of Cytokine-Induced Killer Cell Immunotherapy for Patients With Pathologically Pure Glioblastoma

The most common malignant central nervous system tumor is glioblastoma multiforme (GBM). Cytokine-induced killer (CIK) cell therapy is a promising type of adoptive cell immunotherapy for various cancers. We previously conducted a randomized clinical trial on CIK cell therapy in patients with GBM. Th...

Full description

Bibliographic Details
Main Authors: Myung-Hoon Han, Jae Min Kim, Jin Hwan Cheong, Je Il Ryu, Yu Deok Won, Gun He Nam, Choong Hyun Kim
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Oncology
Subjects:
glioblastoma multiforme
cytokine-induced killer cell (CIK)
immunotherapy
adoptive cell transfer
overall survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.851628/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.851628/full

Similar Items